Dermapharm Holding SE
DMPHF
$38.50
-$2.12-5.23%
OTC PK
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 1.29B | 1.29B | 1.29B | 1.27B | 1.24B |
| Total Other Revenue | 799.50K | 799.50K | 799.50K | 456.50K | 456.50K |
| Total Revenue | 1.29B | 1.29B | 1.29B | 1.27B | 1.24B |
| Cost of Revenue | 472.85M | 482.71M | 482.05M | 476.86M | 469.16M |
| Gross Profit | 822.04M | 805.00M | 811.64M | 796.78M | 771.39M |
| SG&A Expenses | 320.91M | 314.82M | 310.69M | 306.52M | 305.03M |
| Depreciation & Amortization | 85.97M | 88.50M | 88.92M | 90.06M | 89.82M |
| Other Operating Expenses | 166.11M | 166.39M | 171.85M | 167.48M | 163.10M |
| Total Operating Expenses | 1.05B | 1.05B | 1.05B | 1.04B | 1.03B |
| Operating Income | 249.06M | 235.28M | 240.17M | 232.72M | 213.44M |
| Income Before Tax | 177.46M | 169.39M | 186.45M | 154.25M | 140.69M |
| Income Tax Expenses | 62.49M | 59.99M | 65.22M | 56.96M | 52.99M |
| Earnings from Continuing Operations | 114.98 | 109.40 | 121.22 | 97.29 | 87.70 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 1.36M | 1.82M | 2.19M | 1.35M | 2.38M |
| Net Income | 116.34M | 111.21M | 123.41M | 98.65M | 90.08M |
| EBIT | 249.06M | 235.28M | 240.17M | 232.72M | 213.44M |
| EBITDA | 322.84M | 310.30M | 315.52M | 307.73M | 288.19M |
| EPS Basic | 2.16 | 2.06 | 2.29 | 1.83 | 1.67 |
| Normalized Basic EPS | 2.18 | 2.09 | 2.30 | 1.92 | 1.79 |
| EPS Diluted | 2.16 | 2.06 | 2.29 | 1.83 | 1.67 |
| Normalized Diluted EPS | 2.18 | 2.09 | 2.30 | 1.92 | 1.79 |
| Average Basic Shares Outstanding | 215.05M | 215.44M | 215.41M | 215.85M | 215.93M |
| Average Diluted Shares Outstanding | 215.05M | 215.44M | 215.41M | 215.85M | 215.93M |
| Dividend Per Share | 0.96 | 0.96 | 0.96 | 0.95 | 0.95 |
| Payout Ratio | 44.77% | 46.84% | 42.21% | 52.80% | 0.00% |